Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

1,387 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
HER-2/neu evaluation in breast cancer are we there yet?
Winston JS, Ramanaryanan J, Levine E. Winston JS, et al. Among authors: levine e. Am J Clin Pathol. 2004 Jun;121 Suppl:S33-49. doi: 10.1309/9UNL7UXPYO6CPWBQ. Am J Clin Pathol. 2004. PMID: 15298149 Review.
MammaPrint guides treatment decisions in breast Cancer: results of the IMPACt trial.
Soliman H, Shah V, Srkalovic G, Mahtani R, Levine E, Mavromatis B, Srinivasiah J, Kassar M, Gabordi R, Qamar R, Untch S, Kling HM, Treece T, Audeh W. Soliman H, et al. Among authors: levine e. BMC Cancer. 2020 Jan 31;20(1):81. doi: 10.1186/s12885-020-6534-z. BMC Cancer. 2020. PMID: 32005181 Free PMC article. Clinical Trial.
Systemic infusion of TLR3-ligand and IFN-α in patients with breast cancer reprograms local tumor microenvironments for selective CTL influx.
Gandhi S, Opyrchal M, Grimm MJ, Slomba RT, Kokolus KM, Witkiewicz A, Attwood K, Groman A, Williams L, Tarquini ML, Wallace PK, Soh KT, Minderman H, Maguire O, O'Connor TL, Early AP, Levine EG, Kalinski P. Gandhi S, et al. J Immunother Cancer. 2023 Nov;11(11):e007381. doi: 10.1136/jitc-2023-007381. J Immunother Cancer. 2023. PMID: 37963636 Free PMC article.
Association of 70-Gene Signature Assay Findings With Physicians' Treatment Guidance for Patients With Early Breast Cancer Classified as Intermediate Risk by the 21-Gene Assay.
Tsai M, Lo S, Audeh W, Qamar R, Budway R, Levine E, Whitworth P, Mavromatis B, Zon R, Oldham D, Untch S, Treece T, Blumencranz L, Soliman H. Tsai M, et al. Among authors: levine e. JAMA Oncol. 2018 Jan 11;4(1):e173470. doi: 10.1001/jamaoncol.2017.3470. Epub 2018 Jan 11. JAMA Oncol. 2018. PMID: 29075751 Free PMC article.
Randomized phase II trial of fulvestrant alone or in combination with bortezomib in hormone receptor-positive metastatic breast cancer resistant to aromatase inhibitors: a New York Cancer Consortium trial.
Adelson K, Ramaswamy B, Sparano JA, Christos PJ, Wright JJ, Raptis G, Han G, Villalona-Calero M, Ma CX, Hershman D, Baar J, Klein P, Cigler T, Budd GT, Novik Y, Tan AR, Tannenbaum S, Goel A, Levine E, Shapiro CL, Andreopoulou E, Naughton M, Kalinsky K, Waxman S, Germain D. Adelson K, et al. Among authors: levine e. NPJ Breast Cancer. 2016 Dec 14;2:16037. doi: 10.1038/npjbcancer.2016.37. eCollection 2016. NPJ Breast Cancer. 2016. PMID: 28721390 Free PMC article.
1,387 results